Drug Trial Radar · NCT01227967
Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
Last checked: Nov 20, 2026Latest source record: Feb 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
881
Actual
Start
Sep 2010
Primary completion
May 2, 2016
Study completion Mar 30, 2017
Sponsor
- Sponsor type
- NIH
- First posted
- Oct 25, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Seasonal influenza is responsible for many hospitalizations and deaths each year, despite effective antiviral treatments. Some individuals have medical conditions such as heart or lung diseases that make them particularly at risk of severe influenza infections that may result in hospitalization or death. Oseltamivir (Tamiflu) is used most often to treat flu, but there are still many hospitalizations, complications, and deaths even with treatment. This study evaluated the use of combination antivirals (amantadine, oseltamivir, and ribavirin) compared to oseltamivir alone in the treatment of influenza in an at-risk population.
Conditions
- Influenza
Interventions
Amantadine, Ribavirin, OseltamivirDrug
Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg, three capsules of Ribavirin 200 mg for total of 600 mg, and one capsule of Amantadine 100 mg.
OseltamivirDrug
Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) SwabsTime frame: At Day 3
Locations
91 sites in 5 countries. Site status is shown where the registry gives one.
Simon Williamson Clinic
Birmingham, Alabama
East Valley Family Physicians
Chandler, Arizona
Thomas Lenzmeier Family Practice
Glendale, Arizona
Central Phoenix Medical Center
Phoenix, Arizona
WCCT Global LLC
Costa Mesa, California
Advanced Rx Clinical Research
Garden Grove, California
Torrance Clinical Research Institute, Inc.
Lomita, California
University of Southern California
Los Angeles, California
University of California at San Diego
San Diego, California
Westlake Medical Research (CA)
Thousand Oaks, California
Los Angeles BioMedical Research Institute
Torrance, California
Empire Clinical Research
Upland, California
University of Colorado
Aurora, Colorado
Centennial - IMMUNOe International Research
Centennial, Colorado
University of Florida
Gainesville, Florida
Best Quality Research Inc.
Hialeah, Florida
San Marcus Research Clinic, Inc.
Miami, Florida
Medical Consulting Center
Miami, Florida
Suncoast Research Group, LLC
Miami, Florida
University of Miami
Miami, Florida
DMI Research, Inc.
Pinellas Park, Florida
Northwestern University
Chicago, Illinois
Sneeze, Wheeze & Itch Associates, LLC
Normal, Illinois
Ridge Family Practice
Council Bluffs, Iowa
University of Iowa
Iowa City, Iowa
Research Integrity, LLC
Owensboro, Kentucky
Horizon Research Group, of Opelousas, LLC
Eunice, Louisiana
Centex Studies Inc. - Dr. Seep
Lake Charles, Louisiana
NIH Clinical Center
Bethesda, Maryland
Boston Medical Center
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
UMass Medical School
Worcester, Massachusetts
Henry Ford Health Systems
Detroit, Michigan
Bronson Methodist Hospital
Kalamazoo, Michigan
West Florissant Internists
Bridgeton, Missouri
Clinical Research Advantage/ Skyline Medical Center
Elkhorn, Nebraska
Prairie Fields Family Medicine
Fremont, Nebraska
Southwest Family Physicians
Omaha, Nebraska
New Jersey Medical School
Newark, New Jersey
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.